Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Sr. VP-Quality & Manufacturing | April 30, 2018 | May 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2028-04-29 | Direct | 150,000 |
Reported balance
After 2018-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-30 · Grant · Acquired 150,000 · Balance 150,000 F1: 25% of the shares on April 30, 2019 and the remaining shares vest in equal monthly installments over the next 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares on April 30, 2019 and the remaining shares vest in equal monthly installments over the next 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2018 Filed May 2, 2018 21:01 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000905718-18-000446 · matinasbiop_fm4apr302018.xml · derivative · entry 1 DiPaolo Dominick · CIK 0001704277 · Sr. VP-Quality & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-04-29 F1 · derivative.exercise_date: 25% of the shares on April 30, 2019 and the remaining shares vest in equal monthly installments over the next 36 months. Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 21:39 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000905718-17-000855 · dipaolo_fm4sept282017.xml · derivative · entry 1 DiPaolo Dominick · CIK 0001704277 · Senior VP of Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2027-09-28 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on September 30, 2017. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| April 10, 2017 Filed Apr 21, 2017 20:07 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 350,000 | $2.86 Strike: $2.86 | $1,001,000.00 |
DisclosureSEC source: 0000905718-17-000487 · dipaolo_fm4apr102017.xml · derivative · entry 1 DiPaolo Dominick · CIK 0001704277 · Senior VP of Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2027-04-10 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on April 30, 2017. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.